SCM
ECYT

Stevens Capital Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Stevens Capital Management’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-10,695
Closed -$67K – 1354
2014
Q4 		$67K Buy
+10,695
New +$65.2K ﹤0.01% 947

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Stevens Capital Management's ECYT Position: Q1 2015 in Review

Stevens Capital Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q1 2015, closing a stake of 10,695 shares — an estimated $67K sold.

Stevens Capital Management first reported a position in ECYT in Q4 2014 and held it in 1 quarter. The position peaked at $67K in Q4 2014. 98 funds tracked by Wall St. Rank hold ECYT as of Q1 2015.

  • Stevens Capital Management reported no remaining Endocyte, Inc. Common Stock position as of Q1 2015 after selling out during the quarter.
  • Stevens Capital Management sold 10,695 Endocyte, Inc. Common Stock shares in Q1 2015, an estimated $67K.
  • Stevens Capital Management first reported a position in Endocyte, Inc. Common Stock in Q4 2014 and held it in 1 quarter.
  • Stevens Capital Management's Endocyte, Inc. Common Stock position peaked at $67K in Q4 2014.
  • 98 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q1 2015.

Based on Stevens Capital Management's 13F filing for Q1 2015, filed 7 May 2015.